Neurocrine Biosciences (NBIX) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Neurocrine Biosciences (NBIX)

NBIX 141.80

+1.0%

Dec 31 3:59 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: keokalani'nui who wrote (1145)	6/18/2003 12:52:07 PM
From: quidditch	Read Replies (1) of 1834

Wilder, Here is the portion of GS's comment relating to PFE that addresses indiplon: Key products where our forecasts have improved are: − Indiplon: Pfizer’s insomnia drug is currently in Phase III and we are expecting a late 2004 launch, this product was in−licensed from Neurocrine. We are establishing a peak sales estimate of now $700 mm from no estimate. When Phase III trials complete, indiplon will have been tested in 6,163 patients in 52 trials. Filing will address a range of disorders from sleep initiation, sleep maintenance, long−term dosing and middle−of−the−night wakening. Marketing will focus on changing the perception of insomnia from a short−term issue with concerns about drug dependence, to giving physicians comfort with longer−term use. Metabolic interactions should be clean as the drug is metabolized by two separate pathways, CYP3A4 and carboxylesterase. CYP3A4 blockers do not alter indiplon metabolism, which is promising from a drug−drug interaction standpoint. quid

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next